INTRODUCTION
There are many patients with a long-standing history of cigarette smoking who have persistent expiratory airflow obstruction despite partial reversibility with therapeutic intervention. Furthermore, approximately 15-20% may have phenotypic clinical features of both asthma and chronic obstructive pulmonary disease (COPD) [1 && ]. In some cases, a history of asthma has preceded the development of cigarette smokingrelated COPD, and markers of type 2 or eosinophilic inflammation have been noted, including increased blood eosinophils, IgE [1 && ], and hyperresponsive airways. Recently, this epiphenomenon has been labeled the asthma-COPD overlap syndrome (ACOS). We have recently reviewed ACOS in detail [1 && ], and our present goal is to update the reader with respect to diagnosis, treatment, pathophysiology, and markers of inflammation in ACOS. and colleagues hypothesized that the various forms of airway obstruction, such as asthma, chronic bronchitis, and emphysema, should be considered as different clinical and phenotypic expressions of one common disease origin. They named this entity 'chronic nonspecific lung disease' [2] . They proposed that multiple exogenous and endogenous factors including atopy and hyperresponsiveness influenced pathogenesis [2] . Subsequently, at the Third International Bronchitis Symposium in the Netherlands in 1969, Fletcher and Pride suggested the term 'Dutch hypothesis' for the original proposal by Orie and colleagues [3] . Alternatively, in 1991 Vermeire and Pride [4] emphasized that despite common clinical and phenotypic features in COPD and asthma, the origins were distinctly different. In 2006, Kraft [5] and Barnes [6] debated the clinical and pathophysiologic similarities (Dutch hypothesis) [5] versus differences (British hypothesis) [6] between asthma and COPD. Postma and colleagues [7 && ] recently provided an in-depth analysis of the multiple endogenous and exogenous factors that influence the phenotypic homogeneity and heterogeneity in asthma versus COPD and ACOS. Further, recent in-depth reviews have addressed the diagnostic and therapeutic dilemma in COPD patients with presumptive ACOS [ 
CURRENT UNDERSTANDING OF EOSINOPHILIC AND TYPE 2 INFLAMMATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Genome wide association studies suggest, at most, only a weak genetic component to ACOS [21 && ,22 && ]. However, there is increasing evidence that eosinophilic and type 2 inflammation, typically associated with asthma, may play a role in COPD as well. These studies suggest that ACOS is not limited to a clinical phenotype, as there may be a COPD subgroup, or endotype, biologically similar to asthma as well. Eosinophils, as a biomarker for treatment response to asthma-relevant therapeutics, have been studied extensively in COPD. Elevated levels of sputum eosinophils are found in 20-40% of COPD patients [23] . They are associated with small improvements in forced expiratory volume in 1 second (FEV 1 ) and symptom scores after treatment with systemic and inhaled corticosteroids (ICS) in small randomized controlled trials (RCT) in COPD [24] [25] [26] . Furthermore, treatment strategies aimed at reducing sputum eosinophil levels in COPD are associated with decreased rates of severe exacerbations [27] . More recently, blood eosinophil counts have been used in larger studies to estimate airway eosinophil levels as a more readily attainable surrogate measurement. Increased blood eosinophil counts are associated with improvements in exacerbation rates following the addition of ICS to a longacting b 2 -agonist (LABA) in secondary analyses of 2 large RCTs [28] . Also, a phase 2a RCT of benralizumab, the anti-interleukin-5-receptor monoclonal antibody that depletes eosinophils, was recently studied in COPD patients with high sputum eosinophil counts. The primary analysis did not show a difference in acute exacerbations. However, a prespecified subgroup analysis showed a trend toward improved responsiveness in study participants with high blood eosinophil counts [29] . Together these findings suggest that eosinophil levels are elevated in a COPD subgroup and associated with responsiveness to therapeutics. The type 2-associated proinflammatory pathway has been studied less thoroughly in COPD. This is, at least partially, because of the difficulty of obtaining direct measurements of the type 2 cytokines, IL-4, IL-5, and IL-13, in readily available biospecimens. Our recent study instead used airway epithelial gene expression alterations to identify type 2-associated inflammation [30 && ]. We found that type 2-associated gene expression alterations were elevated in a COPD subgroup and were associated with increased eosinophil levels, greater bronchodilator reversibility, and improvements in measurements of hyperinflation. This suggests that type 2-associated inflammation may, in addition to eosinophilic inflammation, play a role in COPD pathophysiology in a subset of patients.
Finally, a recent study [31 && ] used cluster analysis to identify similarities and differences between asthma and COPD. Severe asthma and moderateto-severe COPD patients was examined using
KEY POINTS
Subgroups of smoking-related COPD patients with preexisting and/or current asthma symptoms may have overlapping immune responses including eosinophilia and type 2 inflammation. This epiphenomenon is called asthma-COPD overlap syndrome.
Treatment of ACOS should follow asthma paradigm guidelines including ICS, LABA, LAMA, and oral corticosteroid as needed.
Never-smoked asthma patients may have persistent expiratory airflow limitation because of loss of lung elastic recoil and develop a COPD phenotype like ACOS. This may be because of unsuspected centrilobular emphysema not easily appreciated on lung CT and/or diffusing capacity.
sputum cell counts and cytokines levels as predictor variables. The patients clustered into three distinct groups: asthma-predominant with high type 2 cytokines, COPD-predominant with high proinflammatory cytokines, and both asthma and COPD with greater sputum neutrophilia, cough, and bacterial colonization. This study thus found evidence for ACOS on a biological level, with the largest overlap amongst study participants in which nontype 2 or eosinophil-driven inflammation predominates. The findings may have been skewed by the corticosteroid use in both asthma and COPD study participants, particularly the systemic corticosteroid use in the asthma study participants. Nonetheless, this study [31 && ] suggests that there may be considerable overlap between asthma and COPD patients and that this overlap may extend beyond eosinophilic and type 2 inflammation.
TREATMENT OF ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME
The identification and treatment of the ACOS patient has been recently addressed in a joint initiative from the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [ [15] [16] [17] [18] [19] are cross sectional and lacking randomized controlled therapeutic intervention. Furthermore, biomarker work suggests that the study participants most likely to benefit from directed therapies, such as ICS, may not be easily identified only by clinical characteristics [30 && ]. Furthermore, Barnes emphasizes there is a putative role for novel therapeutics beyond those in our current arsenal (e.g., LABA, LAMA, ICS, oral corticosteroid, and omalizumab) [34 && ]. These therapies may target ACOS-relevant inflammatory pathways or the proteolytic cascade with a goal of preventing irreversible structural changes [34 && ]. Barnes describes multiple therapies relevant to eosinophilic and type 2 inflammation, including the monoclonal antibodies against IL-5, IL-13, IL-33, and thymic stromal lymphopoietin, and the oral chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist. Barnes also describes antineutrophil interventions, which may be more relevant to ACOS than asthma, given the role of neutrophilic inflammation in COPD. Antineutrophilic interventions of potential use could include macrolides, common chemokine receptor antagonists, phosphodiesterase-4 inhibitors, p38 mitogen-activated protein kinase inhibitors, and antibodies against IL-1 and IL-17. However, their therapeutic role in ACOS remains unproven.
MECHANISM(S) FOR PERSISTENT EXPIRATORY AIRFLOW LIMITATION IN TREATED, NEVER-SMOKED, CHRONIC ASTHMA PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHENOTYPE
Until recently, structure-function studies have not specifically addressed the unique pathophysiologic mechanism(s) responsible for persistent expiratory airflow limitation in nonsmoking chronic asthma patients who develop a COPD phenotype similar to ACOS in smokers. In nonsmoking asthma patients, we [35 && ,36 && ] and other investigators have reported reversible loss of lung elastic recoil and hyperinflation at total lung capacity during acute attacks of asthma. Loss of lung elastic recoil has also been reported in mild asthma patients and in asthma patients with only partially reversible airway obstruction despite treatment [35 && ,36 && ]. The sentinel study in 1967 by Gold, Kaufman, and Nadel [37] reported the reversible loss of lung elastic recoil in acute asthma. In 1968, Woolcock and Read [38] noted the persistent loss of lung elastic recoil in stable nonsmoking moderate-to-severe asthma patients with chronic expiratory airflow limitation despite treatment. Furthermore, with exacerbations of asthma, there was a near-parallel further shift to the left of the pressure-volume curve [38] . The unexpected loss of lung elastic recoil in nonsmoking asthma patients contributes greatly to exaggerate any expiratory airflow limitation because of intrinsic peripheral airway bronchoconstriction [ && ] unsuspected diffuse microscopic mild centrilobular emphysema in formalin-inflated lungs obtained at autopsy in all four severe asthma cases, despite normal diffusing capacity. The lung tissue breakdown was not consistent with senile emphysema as originally described by Verbeken et al. [39] . Furthermore, only mild emphysema at most was identified on highresolution, thin-section lung CT including voxel quantification. There were also concurrent microscopic findings of typical asthma changes in both large and small airways, including mucosal goblet cell metaplasia, and thickening of both the basement membranes and airway smooth muscle layers [35 && ,36 && ]. These pathophysiologic findings extend earlier novel pathologic observations by Mauad et al. [40] . They described localized periterminal bronchiolar emphysema with breakdown of alveolar attachments in autopsied fatal asthma patients without lung function studies [40] . The inflammatory lung response described in these same study participants included increased eosinophils, mast cells, and neutrophils in the peribronchiolar parenchyma [41, 42] . The outer wall of small membranous bronchioles was the main site of these inflammatory changes [42] . Recently, Senhorini et al. [43] noted that younger adult fatal asthma patients had thicker basement membranes, smooth muscle and outer wall areas, in both small and large airways when compared with both COPD and older asthma patients. In older asthma patients, there was an overlap in basement membrane thickness and airway structure in small airway. Inner wall layer in large and small airways and submucosal gland areas were similar among groups. Older fatal asthma patients had overlapping airway structural features with younger adult fatal asthma patients and severe COPD patients [43] .
MECHANISM(S) RESPONSIBLE FOR THE INFLAMMATORY AND PROTEOLYTIC LUNG TISSUE BREAKDOWN IN CHRONIC NON-SMOKING ASTHMA PATIENTS
The original description of emphysema by Leopold and Gough [44] suggested that the terminal bronchioles were the nascent site of lung tissue breakdown that led to centrilobular emphysema. As recently summarized [1 && ,35 && ,36 && ], we suggest that recurrent asthma attacks may produce bronchiolar inflammation with activation of a predominantly type 2-associated proinflammatory pathway and ]. This asthma pathway is similar to the breakdown of terminal bronchiolar attachments to lung parenchyma in smokers with early emphysema, resulting in loss of lung elastic recoil, as described by Saetta et al. [47] . Gelb et al. [48] previously described chronic smokers with severe small airway obstructive disease, who also had mild centrilobular emphysema as confirmed on inflated lungs obtained from autopsy. They all had abnormal FEV 1 (L) and reduced expiratory airflow at both high and low lung volumes, with reduction in both lung elastic recoil and diffusing capacity. However, lung CT revealed only marginal abnormalities and underestimated mild centrilobular emphysema [48] .
CONCLUSION
A subset of smoking-related COPD patients with hyperresponsive airways with and without a history of asthma has been identified, and this ACOS phenotype has been reviewed. Eosinophilic, type 2, and neutrophilic immune responses may all potentially play a role in the overlap between asthma and COPD. Therapeutic intervention for ACOS should reflect the asthma paradigm. However, how to best characterize the subgroup to maximize therapeutic benefit is still unclear.
The review has also emphasized the importance of the mechanism(s) responsible for expiratory airflow limitation in nonsmoking, moderate-to-severe asthma patients with persistent expiratory airflow limitation who develop a COPD phenotype similar to ACOS in smokers. They also have a normal diffusing capacity and mild emphysema abnormalities on lung CT. We suggest that a proinflammatory pathway and proteolytic cascade leading to lung tissue breakdown and unsuspected autopsy proven centrilobular emphysema are key contributors.
